5th Next Generation Gene Therapy Vectors Summit 2025
Achieve Safety through Novel Capsids and Payloads
2024 saw huge investments in gene therapy vectors. Following a $1.1 billion acquisition of Kate Therapeutics by Novartis and a collaboration between Roche and Dyno Therapeutics, which could generate more than $1 billion for Dyno, it’s time to come together and continue unlocking the ever-clearer potential of vector therapies.
Time: 8:00 AM – 4:05 PM
Venue details: Revere Hotel Boston Common, 200 Stuart St, Boston, Massachusetts, 02116, United States
Prices: USD 2599.00 – USD 5097.00
Speakers: Anthony Dinatale, Investment Associate, Agent Capital, Caroline Xu, Co-Founder and CEO, ViGeneron GmbH , and more
Topics: genetherapy, genetherapyvectors, nextgeneration, nextgenerationgenetherapy, genetherapycapsid
Event Organizer: Hanson Wade